Biogen traded at $183.33 this Tuesday March 31st, decreasing $4.24 or 2.26 percent since the previous trading session. Looking back, over the last four weeks, Biogen lost 2.51 percent. Over the last 12 months, its price rose by 38.85 percent. Looking ahead, we forecast Biogen to be priced at 178.32 by the end of this quarter and at 162.75 in one year, according to Trading Economics global macro models projections and analysts expectations.
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.